	US 12,304,940 B2
	HLA class II-restricted t cell receptors against mutated RAS
Gal Cafri, Kibbutz Nir David (IL); Paul F. Robbins, Chevy Chase, MD (US); and Steven A. Rosenberg, Potomac, MD (US)
Assigned to The United States of America, as represented by the Secretary, Department of Health and Human Services, Bethesda, MD (US)
Filed by The United States of America, as represented by the Secretary, Department of Health and Human Services, Bethesda, MD (US)
Filed on Mar. 11, 2022, as Appl. No. 17/692,787.
Application 17/692,787 is a division of application No. 16/135,231, filed on Sep. 19, 2018, granted, now 11,306,132.
Claims priority of provisional application 62/560,930, filed on Sep. 20, 2017.
Prior Publication US 2022/0204584 A1, Jun. 30, 2022
Int. Cl. C07K 14/725 (2006.01); A61K 38/17 (2006.01); A61K 40/11 (2025.01); A61K 40/32 (2025.01); A61K 40/42 (2025.01); A61P 35/00 (2006.01); C07K 14/82 (2006.01); C12N 15/62 (2006.01); G01N 33/574 (2006.01); A61K 40/50 (2025.01)

CPC C07K 14/7051 (2013.01) [A61K 38/177 (2013.01); A61K 40/11 (2025.01); A61K 40/32 (2025.01); A61K 40/4253 (2025.01); A61P 35/00 (2018.01); C07K 14/82 (2013.01); C12N 15/62 (2013.01); G01N 33/5748 (2013.01); A61K 40/50 (2025.01); G01N 2800/7028 (2013.01)]

22 Claims

1. An isolated or purified T-cell receptor (TCR), wherein the TCR has antigenic specificity for a mutated human RAS amino acid sequence presented by a human leukocyte antigen (HLA) Class II molecule,

wherein the mutated human RAS amino acid sequence is a mutated human Kirsten rat sarcoma viral oncogene homolog (KRAS), a mutated human Harvey rat sarcoma viral oncogene homolog (HRAS), or a mutated human Neuroblastoma rat sarcoma viral oncogene homolog (NRAS) amino acid sequence, wherein the TCR comprises:

an α chain complementarity determining region (CDR) 1 comprising the amino acid sequence of SEQ ID NO: 7, an α chain CDR2 comprising the amino acid sequence of SEQ ID NO: 8, an α chain CDR3 comprising the amino acid sequence of SEQ ID NO: 9, a β chain CDR1 comprising the amino acid sequence of SEQ ID NO: 10, a β chain CDR2 comprising the amino acid sequence of SEQ ID NO: 11, and a β chain CDR3 comprising the amino acid sequence of SEQ ID NO: 12.